title: Aliskiren improves vascular smooth muscle function in the skin microcirculation of type 2 diabetic patients with normal renal function.
abstract: OBJECTIVE
  The objective of this paper is to study the effect of aliskiren on metabolic parameters and micro- and macrovascular reactivity in individuals diagnosed with or at high risk for developing type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  We studied 47 T2DM and 41 at-risk individuals in a randomized, double-blinded, placebo-controlled trial. All subjects were treated with 150 mg aliskiren or placebo daily for 12 weeks. Twenty-six (55%) of T2DM and four (8%) at-risk subjects were also treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers.
  
  
  RESULTS
  Aliskiren treatment was associated with improvement in systolic and diastolic blood pressure and endothelium-independent vasodilation at the skin microcirculation in those with T2DM but not in those at risk. There were no incidences of hypotension and no significant changes in serum potassium or creatinine levels with aliskiren treatment in either study group.
  
  
  CONCLUSIONS
  Aliskiren improves blood pressure and vascular smooth muscle function in the skin microcirculation of T2DM patients.
authors.affiliation: Division of Endocrinology, Beth Israel Deaconess Medical Center, USA.
authors.forename: Jody R
authors.initials: JR
authors.lastname: Dushay
authors.affiliation: Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
authors.forename: Francesco
authors.initials: F
authors.lastname: Tecilazich
authors.affiliation: Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
authors.forename: Antonios
authors.initials: A
authors.lastname: Kafanas
authors.affiliation: Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
authors.forename: Mary L
authors.initials: ML
authors.lastname: Magargee
authors.affiliation: Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Auster
authors.affiliation: Technological Educational Institute of Messolonghi, Greece.
authors.forename: Charalambos
authors.initials: C
authors.lastname: Gnardellis
authors.affiliation: Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
authors.forename: Thanh
authors.initials: T
authors.lastname: Dinh
authors.affiliation: Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA aveves@bidmc.harvard.edu.
authors.forename: Aristidis
authors.initials: A
authors.lastname: Veves
mesh_terms: D000577:Amides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D003710:Demography; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D005542:Forearm / Q000473:pathology; D005650:Fumarates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000503:physiopathology*; D012867:Skin / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000577:Amides; D015415:Biomarkers; D005650:Fumarates; C446481:aliskiren
keywords: Type 2 diabetes; aliskiren; prediabetes; vascular smooth muscle